Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
An Oldtimer is highlighting the fact that Sheff reposted the JMP analyst target for NAVB at 5.00. I will be the first to cheer if we see 5.00, but for starters, just hitting 2.00 again (never mind even closing above it) will be almost as impressive as 5.00 given the stagnancy and stranglehold on our pps.
Uri could be very helpful right now if he chose to be...WHY HAS HE BEEN SILENT ON NAVB FOR SO LONG?!
I stand corrected. Woops.
Inside...4,858,400 shares traded on 2/6/14 and I recall thinking at the time that the volume was suspicious for the day, especially considering that there was no news good or bad that day. Something fishy was likely associated with this date...Does it correspond to dates that PM might have unloaded a huge block?
I just don't understand the salary reductions that Pykett and crew had to endure for 2014. I say their pay should all be doubled now and their bonuses should all be tripled and the sooner the better. They have succeeded in destroying the share price since September 2013. Imagine the impact of a CRL in June or October. I don't want or expect any CRL's but with the new trend of doing everything they can to harm the shareholder, two CRL's from the FDA this year and a complete denial from the EU will not shock me one bit. Nor will the shorts refusing to cover in the event of these three potential failures surprise me. They seem to be waiting for the day when NAVB trades at BID .008 X .009. If the current stagnancy and management INATTENTION to shareholders continues, the shorts may not have to wait much longer for the sub-penny level.
How about another Crede deal to the rescue next week. Instead of trading sub-penny too soon, we can at least get the sub-dollar trading underway. Crede shall pay $0.95 "per unit" this time and will receive 80,000,000 shares of common stock and 175,000,000 warrants with a strike price of 1.30. Brent Larson can hype up how great this deal is for the stock and company. Meanwhile, the stock trades at .50 and there is still no short covering.
This is all starting to look like one of the best orchestrated stock scams in recent years. The Crede deal destroyed the share price and PM and the shorts are taking the destruction further. Meanwhile, Pykett, Tulip, and Larson mock and disrespect shareholders. Wonderful.
Considering that he sold 196,000 shares in March 2014, this buy is chicken shit, which is what NAVB stock has become. Even if all insiders bought 10,000 shares today, it is not enough to attract investor interest. Something very destructive is going down with the stock and there is no hint that it is anywhere near done. PM probably bought the shares for Pykett.
Thanks inside. I don't think Lymphoseek sales will be slowing, but the possibility is there.
According to the DDbuyer and toonos, something relating to PM might be coming. We'll all be watching.
Toonos is not always as accurate as he likes to think. In March 2013, one of his posts said, "3.75 is a lock" referring to the PDUFA run that was underway. We all know NAVB did not see 3.75. He likes to brag that he sold out of most if his position last Summer at 3.15. That may be, and if so, it was a smart move given where the pps is now, but it also seems like his doom and gloom posts are aimed at scaring others into selling even lower than the stock is now trading so that he can ride NAVB up all over again. He is self-serving above all else.
One thing that seems very clear is that PM can control the stock one way or another indefinitely, especially if they ever want to own more than 9.99% of the stock. They might be the bulk of the short interest as we'll. After all, if they still own approximately 36 millions shares as DDbuyer maintains, having a short position of at least 10 million shares would go a long way to hedge against their long position...which is now all profit anyways.
Is the new shelf registration related to PM somehow getting more shares AND HOW THE HELL DO THE OLDTIMERS KNOW SO IN ADVANCE? This new rumor will be well worth following.
Inside, unless I am misunderstanding DDbuyer and toonos, they seem to be implying the opposite of what you are posting about the company not needing more cash through 2015. Do you follow what they are saying exactly. It seems as if it relates to PM getting more shares to sell.
Thanks for the great information inside and the impressive link. I think the revenue question for 2015 is the key to future stock price and further necessary dilution or the the lack of further necessary dilution. One thing I am absolutely sure of is that those who sold last week because of the updated and renewed shelf registration made a huge mistake. I do not expect any dilution in the remainder of 2014 under any circumstances and I also believe a 20% turnaround from here is likely as June 16th approaches.
Your research into the more complicated projections and PM selling is appreciated.
Wrinkles, you have done a great job in the past of broadcasting your nickel and dime trades with NAVB on this board. Fine. Last week you said you were fed up with the stock and management. Fine. Yet here you are today questioning my attitude (the attitude of a LONG) who does not flip this stock for pennies. Watch your tone as you appear and disappear from this board when trading NAVB happens to suit you. Stop loss orders are for losers. And if that's you in the boat (or anything remotely close to your body type) lay off the fricking donuts and judging my posts. Investors have legitimate gripes with NAVB as even you did last week, or have you forgotten already?
Shareholders are still paying for the toxic Crede deal. How much market cap and shareholder value evaporates today? Will the stock hold 1.00? The company keeps saying they have no intention to sell another offering of shares. This damn well better be true.
I agree with your entire post. I also think a buyout under 3.00 is insulting, though it seems as if it could happen closer to 2.00 given the continual BS we are seeing. I don't think a buyout under 3.00 would be well received by most retail shareholders. The shareholder meeting in July is going to be very interesting, as is the price action we see leading up to June 16th and after. Right now, this is more disgusting than ever.
Here's a legitimate question that I have not heard anyone ask yet that I think deserves some real attention. Here goes:
Assuming that Navidea is able to get FDA approval in June and October AND is able to get EU approval by the end of 2014, how much will the company's revenue be in 2015?
On the low end and on the high end, what are some reasonable estimates?
I would think at least $30-40 million on the high end, but perhaps it is much greater than this. The SLN designation will be worth far more in sales than breast and melanoma cancer. There must be posters here and elsewhere who have a solid idea. Please advise. This is a forecast worth exploring.
The company seems to be begging for a lowball buyout offer. They should not be allowing this trading action to happen. If the pps stays under 1.50 for three consecutive months, they might get their wish. Crede is selling like there is no tomorrow, yet at least three catalysts are expected in the way of regulatory approvals within the next six months. I'm sure they want the quick buck, but if there is any type of PDUFA run, they make less by selling today than they would selling up to June 16th. If new institutions wanted to start a position here, this is a level that I bet most of us never thought would have been possible (unless we had an FDA denial or European denial). As it is, the sky is not falling, but the God damn company itself and Crede are bringing the sky down all on their own. How many here would be happy with a buyout at 2.09...the bargain price the company fed to Crede and slit our throats with?
I'm hoping that Brent Larson has some hearing loss after today. I did not call him today, but I have to believe that many disgusted investors did. I raised my voice in the extreme when I talked to him. If he has half a brain in his head he should have figured out that I have much more than yelling in mind if things do not improve.
It is time for shareholder lawsuits. If things don't improve, I won't be at all surprised if something terrible happens at the next shareholder meeting.
New short interest information will be out tonight, maybe tomorrow. It seems as if with Platinum selling unlimited quantities of shares, Crede seemingly shorting as well (against their warrants), our old shorts currently with approximately 20,000,000 shares bet against the company, and the dilution overhang made even worse by the new shelf registration, this stock is headed to 1.00 or lower until and unless these four variables stop. There is no hint that these things are stopping anytime soon. Europe is delayed likely until Q4 and I don't even want to imagine how bad the stock will perform if we get an FDA denial next month.
No wonder Crede hasn't redeemed the warrants. The best medicine for this stock would be a complete change in management. I bet the pps would surge to 2.50 if Pykett, Tulip, and Larson were forced to step down.
As it is, unfortuntaely, I don't think they are going anywhere and the shareholder lawsuits are really long overdue. Heaven help Larson - he said on the phone more than once to me that another offering would be unnecessary because of the lines of credit that the company has available.
The pay decreases were a good idea, they just didn't go anywhere near far enough. Is Pykett even worth $100K for this bull shit we have been seeing since September? No. I think all hell could break loose at the next shareholder meeting.
Is the company going to be sold for between 1.75 and 2.25 per share? That is how this is starting to look.
Regardless of how much the head and neck approval will or will not boost the stock, a denial on June 16th could certainly crush it below 1.00. If we get all 3 approvals (including Europe and the October decision) we should recover to somewhere in the mid 2s - especially if the company can find the time to provide a MEANINGFUL update on 4694, 5001, or 1800 - or perhaps they are working with the shorts outright. Nothing surprises me anymore with this sham of a company.
It sure seems as if the company could care less about shareholder value.
Absolutely right. If sales are greater than $1 million, a real turnaround could start tomorrow. As it is, based on the past month of trading, we will be damn lucky to see 1.70 with sales under $1 million tomorrow.
GLTA.
If the pps trends up above 1.64, earnings should be good. If not, earnings will disappoint. The last time NAVB saw 1.99 was the day BEFORE a PR. There are only secrets at Navidea kept from the common shareholder...
An update on NAV4694, NAVB5001, or NAV1800 would be more than welcome right now.
I'll say this again - Since the company has already issued guidance of revenue expectations between $5 million and $6 million for calendar year 2014, sales almost have to be at least $700,000 for this next earnings report or the company is simply lying and misrepresenting everything all the time. I don't see how another report in the $350,000 range could remotely justify guidance for 2014 beyond $2 million.
This is trading in a ridiculous way. Brent Larson is useless on the phone saying how he "is just as frustrated as shareholders are, the company is working diligently, and the company is adhering to its business plan..." NEWS FLASH BRENT: SOMETHING AIN'T WORKING! I for one, wouldn't be against a shareholder lawsuit that aimed to sue the three amigos personally if things don't turnaround soon.
This stock is trading as if we are looking at poor sales next week, an FDA denial is coming on June 16th, and European Approval will not happen at all in 2015. Someone with millions of shares seems to know that NOW is the time to sell. Months ago, many thought that we would be building our pps back between March 24th and June 16th.
If only.
Thanks inside...I find myself wondering if we got early FDA approval TOMORROW (well ahead of our June 16th PDUFA date) if the stock could break through 1.87. 2.00 seems out of the question for now. Earnings above $500,000 will satisfy me next week because this figure will represent substantial growth above and beyond all previous quarters that included Lymphoseek sales.
Our overpaid trio of stooges who seem to be anything but wisemen whose names begin with P, T, and L have much work to do...Hopefully, when the next FDA (or European approval comes) the powers that be will release the news PREMARKET to facilitate a stock run, rather than a noon release that allowed the shorts to get a head start on smacking the hell out of the stock. Heck, they could also do us a favor and not tell Platinum Montaur for 5 extra minutes to limit the initial damage PM will do by unloading millions of shares at a time.
Hey there P, T, and L...can you PLEASE OFFER AN UPDATE ABOUT WHETHER RIGS or 1800 or whatever the hell you are calling it these days is REALLY under development, or is it just a ploy to get investors to roll the dice on NAVB? The last 10Q raised more questions than answers in this regard. TICK TOCK!
GLTA.
Crede MUST have known that Platinum was going to be putting a major stranglehold on the share price which explains why we have not seen evidence of the warrant conversion yet. Something very shady appears to be happening and shareholder lawsuits PLURAL may be inevitable very soon.
There is CERTAINLY the appearance that multiple downward share price factors/entities are working together here to destroy the stock and/or the company once and for all. To make matters worse, Pykett, Tulip, and Larson seem not to care about addressing this disgusting situation one bit.
The NAVB short interest is up another 987,988 shares (5.2%).
How nice it would be to see Pykett, Tulip, and/or Larson earn some of that paycheck and do something in the name of shareholder value.
I didn't read it that way, but I can only hope you are correct. IMO, all bonuses and salaries too from here on out should be based on Lymphoseek sales and newly achieved milestones related to the rest of the pipeline. No one at Navidea deserves even $200K annually based on the absolute nonsense we have seen since September 2013.
A new short interest report should be available tonight. FWIW, I expect at least another 500,000 share increase. All of the short covering that started back in April of 2013 that brought the short interest down from 25 million shares to 18 million seems to be getting reshorted to cap the price at present.
Never forget that regardless of company rationales, explanations, and necessities, $100 million in market cap was thrown away to raise $30 million. If I had my way...I can't say anymore... :)
Yes. I have already reviewed it and it looks as if it is nothing substantial. Just far too much compensation for Pykett and Cornelia B. Reininger who do far too little for shareholder value.
Same old, same old.
Earnings are expected during the period 5/3-5/7. What are folks expecting here? I say, it damn well better be $500K or more, or the company is misleading investors. Their guidance was $5-$6 million for 2014...
I agree, but 1.80 is nothing to get too excited about - this stock was trading at 2.24 X 2.25 in December right before EU approval was delayed...
Nice move up indeed. NAVB seldom holds onto a .15 gain in a day. Maybe the PDUFA run is starting...
GLTA.
I believe (and gosh darn demand) that the company get a RIGS partner and/or a 4694 partner immediately. This will turn things around perpetually. This would be the best case for NAVB, assuming of course, that we also get both expected FDA approvals later this year and European approval (which seems to be dragging on for no good reason that the shareholder is aware of). Lymphoseek alone does not make Navidea a 2.00 stock with abominable sales quarter after quarter. I do not think we will be on the April or May European calendar given the ridiculous delay that continues with Eurpope. June will be wonderful for EU approval, but who knows...
The worst case for NAVB from here on out imo, is the complete abandonment of RIGS, the complete failure of 4694, and the complete failure of 5001. Along the way, as these pipeline products fail or are abandoned, another share offering (or two) will occur and the stock will go under 1.00, never again to trade above 1.00.
Perhaps the Crede deal was the beginning of the end for this company. Nothing is helping the stock.
I lead the pack in voicing disgust and dissatisfaction with Navidea management, but this analyst report from today is nothing more than a hit piece aimed at adding downward pressure to a weak NAVB and just before the PDUFA run to June 16th should be starting. Short interest increased by over 1,000,000 shares in the second half of last month. Clearly, the shorts are not giving up, but I believe the tug of war should be getting harder for them over the next 60 trading days (and perhaps much sooner).
GLTA.
Another thing I thought of recently is that instead of doing the Crede deal, the company could have sold the 10,000,000 shares on the open market gradually without having the same deleterious and thoughtless effect on the shareprice. As it is, with the pps languishing EVEN WITH NEWS it still seems as if the whole arrangement was designed to ruin the pps for a long while, and since no forms have been filed regarding the Crede warrants that were supposed to be available to Crede on 3/24, it seems as if we have more stagnancy and decline in our future at least until Crede is finally done with Navidea. Selling shares on the open market would have negated the need for warrants and the stranglehold on the pps we continue to see as the PDUFA dates approach. Unreal.
Disgusting and unacceptable - and I only hold 36,000 shares. The Oldtimers restraint in their posts, assuming that message board still owns upwards of 10-12 million shares is a miracle.
GLTA.
I notice that wise old DDbuyer has been quite silent for months relying on posts that merely highlight analysts more often than not...
I'd like to know if he thinks NAVB is still in "stupid territory" trading in the 1.70s when he posted months ago that the 2.40s were "stupid territory" following FDA approval of Lymphoseek last Spring.
This article is solid and accurate...I just maintain that the company needs to blow its own horn a lot louder starting yesterday.
There is a PR today on Manocept and K. Sarcoma. It reads well.
We are expecting the next earnings call in early May - essentially a full month from now. If we get no positive PR before then and lousy sales numbers yet again, it will be ever more obvious that the company is a sham. With as many known catalysts that the company says are coming soon, this stock should not be weak IT SHOULD BE STRONG.
Wouldn't a nice surprise like a RIGS trial update be nice right about now? That started in December. News on that front should be coming.
It sure seems like the Crede deal is still taking a toll on shareholders.
And it's up .08 on very light volume...Nice to see. As far as I am concerned though, it is the job of Pykett, Tulip, and Larson to promote this company and move the stock with developments and milestones, not Seeking Alpha. It is time for the company to sit or get off the pot...successfully develop the pipeline or sell the company to a bigger (and far more competent pharmaceutical that will get things done).
Put another way, management's inaction and inattentiveness to shareholders, shareholder value, and currently VERY POOR share price performance needs to be addressed IMMEDIATELY. As it is, I sometimes wonder if the company is intentionally working to keep the share price deflated...but for the life of me, I can't think of a legal reason why they would or should.